NAS:GENE (Australia)  
Genetic Technologies Ltd logo

Genetic Technologies Ltd

$ 1.17 -0.0471 (-3.88%) 10:08 PM EST
P/E:
At Loss
P/B:
2.00
Market Cap:
$ 17.97M
Enterprise V:
$ 16.83M
Volume:
16.62K
Avg Vol (2M):
67.62K
Also Trade In:
Volume:
16.62K
Market Cap $:
17.97M
PE Ratio:
At Loss
Avg Vol (2-Month):
67.62K
Enterprise Value $:
16.83M
PB Ratio:
2.00
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Name Current Vs Industry Vs History
Cash-To-Debt 17.99
Equity-to-Asset 0.79
Debt-to-Equity 0.04
Debt-to-EBITDA -0.1
Interest Coverage 224.27
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.22
Distress
Grey
Safe
Beneish M-Score 68.96
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 2.99
9-Day RSI 11.76
14-Day RSI 21.44
6-1 Month Momentum % -25.38
12-1 Month Momentum % -52.43

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.86
Quick Ratio 3.76
Cash Ratio 3.08
Days Inventory 307.01
Days Sales Outstanding 58
Days Payable 1084.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -43.1
Name Current Vs Industry Vs History
Gross Margin % 95.28
Operating Margin % 49.51
Net Margin % -104.94
ROE % -37.26
ROA % -32.26
ROIC % 59.96
ROC (Joel Greenblatt) % -779.78
ROCE % -36.76

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 4
PB Ratio 2
EV-to-EBIT -3.62
EV-to-EBITDA -3.94
EV-to-Revenue 3.81
EV-to-FCF -4.49
Earnings Yield (Greenblatt) % -27.62

Financials (Next Earnings Date:2023-02-24 Est.)

GENE's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:GENE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 4.801
EPS (TTM) ($) -0.341
Beta 1.5
Volatility % 59.44
14-Day RSI 21.44
14-Day ATR ($) 0.075655
20-Day SMA ($) 1.391895
12-1 Month Momentum % -52.43
52-Week Range ($) 0.95 - 3.27
Shares Outstanding (Mil) 15.39

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Genetic Technologies Ltd Filings

Document Form Filing Date
No Filing Data

Genetic Technologies Ltd Analysis

Share your research

Headlines

See More
No news.